In terms of fundamentals, Pfizer currently boasts a market capitalization of $132 billion. Over the last twelve months, the ...

PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar ...

Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the ...

Trade deficit data, Federal Reserve officials' remarks, earnings from Pfizer, Disney, Uber, and additional companies.

Amazon's $4B stake in Anthropic and deep AWS integration boost enterprise AI adoption. Click here to find out how Claude ...

Revenue (GAAP) missed expectations, falling to $156.8 million in Q2 2025—down approximately 14% from the prior year quarter and 5.4% below analyst estimates. GAAP net loss deepened to $0.19 per share, ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Alnylam Pharmaceuticals, Inc. shares soar with strong Q2 results, driven by Amvuttra's stellar U.S. launch for ATTR ...

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...

An increasing number of analysts are pointing out that the AI revolution that started with the launch of ChatGPT is here to ...

Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, ...

A stellar launch of rare heart disease med Amvuttra has boosted Alnylam’s market cap above $50 billion. | A stellar launch of Amvuttra in the rare heart disease ATTR-CM has boosted Alnylam’s market ...